A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020

ROS1 fusion–positive (ROS1+) NSCLC was discovered in 2007, the same year as the discovery of ALK-positive (ALK+) NSCLC but has trailed ALK+ NSCLC in terms of development. There seems to be a differential response to ROS1 inhibitors, which depend on fusion partners (CD74, SLC34A2, or SDC4); thus, kno...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Sai-Hong Ignatius, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474457/
https://www.ncbi.nlm.nih.gov/pubmed/34589944
http://dx.doi.org/10.1016/j.jtocrr.2020.100048
_version_ 1784575228283715584
author Ou, Sai-Hong Ignatius
Nagasaka, Misako
author_facet Ou, Sai-Hong Ignatius
Nagasaka, Misako
author_sort Ou, Sai-Hong Ignatius
collection PubMed
description ROS1 fusion–positive (ROS1+) NSCLC was discovered in 2007, the same year as the discovery of ALK-positive (ALK+) NSCLC but has trailed ALK+ NSCLC in terms of development. There seems to be a differential response to ROS1 inhibitors, which depend on fusion partners (CD74, SLC34A2, or SDC4); thus, knowledge of the fusion partners in ROS1+ NSCLC is important. To date (end of February 2020), we have identified 24 unique 5’ fusion partners of ROS1 in ROS1+ NSCLC from published literature and congress proceedings. Thus, we published this catalog for easy reference.
format Online
Article
Text
id pubmed-8474457
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84744572021-09-28 A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020 Ou, Sai-Hong Ignatius Nagasaka, Misako JTO Clin Res Rep Review Article ROS1 fusion–positive (ROS1+) NSCLC was discovered in 2007, the same year as the discovery of ALK-positive (ALK+) NSCLC but has trailed ALK+ NSCLC in terms of development. There seems to be a differential response to ROS1 inhibitors, which depend on fusion partners (CD74, SLC34A2, or SDC4); thus, knowledge of the fusion partners in ROS1+ NSCLC is important. To date (end of February 2020), we have identified 24 unique 5’ fusion partners of ROS1 in ROS1+ NSCLC from published literature and congress proceedings. Thus, we published this catalog for easy reference. Elsevier 2020-04-28 /pmc/articles/PMC8474457/ /pubmed/34589944 http://dx.doi.org/10.1016/j.jtocrr.2020.100048 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Ou, Sai-Hong Ignatius
Nagasaka, Misako
A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
title A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
title_full A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
title_fullStr A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
title_full_unstemmed A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
title_short A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
title_sort catalog of 5’ fusion partners in ros1-positive nsclc circa 2020
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474457/
https://www.ncbi.nlm.nih.gov/pubmed/34589944
http://dx.doi.org/10.1016/j.jtocrr.2020.100048
work_keys_str_mv AT ousaihongignatius acatalogof5fusionpartnersinros1positivensclccirca2020
AT nagasakamisako acatalogof5fusionpartnersinros1positivensclccirca2020
AT ousaihongignatius catalogof5fusionpartnersinros1positivensclccirca2020
AT nagasakamisako catalogof5fusionpartnersinros1positivensclccirca2020

Ejemplares similares